CymaBay Therapeutics Inc. (NASDAQ:CBAY) saw an upside of 5.32% to close Tuesday at $13.06 after adding $0.66 on the day. The 5-day average trading volume is 1,516,040 shares of the company’s common stock. It has gained $13.34 in the past week and touched a new high 2 times within the past 5 days. An average of 1,402,405 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,067,158.
CBAY’s 1-month performance is 10.40% or $1.48 on its low of $11.27 reached on 08/18/23. The company’s shares have touched a 52-week low of $3.15 and high of $14.19, with the stock’s rally to the 52-week high happening on 08/11/23. YTD, CBAY has achieved 108.29% or $6.79 and has reached a new high 30 times. However, the current price is down -7.96% from the 52-week high price.
Insider Transactions
CBAY stock investors last saw insider trading activity on Aug 18.McWherter Charles (President of R&D) most recently sold 21,746 shares at $11.47 per share on Aug 18. This transaction cost the insider $249,359. General Counsel, Quinlan Paul T, sold 5,000 shares at a price of $11.91 on Aug 15. Then, on Aug 09, Vice President, Finance Menold Daniel sold 20,945 shares at a price of $12.35 per share. This transaction amounted to $258,744.
Valuation Metrics
CBAY stock has a beta of 0.37. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 40.34 while the price-to-book (PB) in the most recent quarter is 12.32.
CymaBay Therapeutics Inc.’s quick ratio for the period ended June 29 was 12.50, with the current ratio over the same period at 12.50. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.92, while the total debt to equity was 0.92. The firm’s gross profit as reported stood at $14.91 million against revenue of $93.11 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income shrunk -3244.44% to -$0.81 million, while revenue of -$28.78 million was -3453.09% off the previous quarter. Analysts expected CBAY to announce -$0.2 per share in earnings in its latest quarter, but it posted -$0.01, representing a 95.00% surprise. EBITDA for the quarter stood at more than -$1.88 million. CBAY stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 118.24 million, with total debt at $99.62 million. Shareholders hold equity totaling $98.15 million.
Let’s look briefly at CymaBay Therapeutics Inc. (CBAY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 59.58% to suggest the stock is trending Neutral, with historical volatility in this time period at 90.81%.
The stock’s 5-day moving average is $12.17, reflecting a +1.63% or $0.21 change from its current price. CBAY is currently trading +11.24% above its 20-day SMA, +49.26% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +42.58% and SMA200 by+275.29%.
Stochastic %K and %D was 40.30% and 25.61% and the average true range (ATR) pointed at 0.86. The RSI (14) points at 58.77%, while the 14-day stochastic is at 61.30% with the period’s ATR at 0.80. The stock’s 9-day MACD Oscillator is pointing at -0.02 and 0.01 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for CymaBay Therapeutics Inc. (NASDAQ: CBAY), UBS launched coverage with a Buy rating. Analysts offering their rating for CBAY stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CBAY as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 13 have offered a “buy” rating.
What is CBAY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $12.00 and a high of $22.00, with their median price target at $17.50. Looking at these predictions, the average price target given by analysts is for CymaBay Therapeutics Inc. (CBAY) stock is $17.42.
